JMP cited strong prescription growth of 7% quarter-over-quarter for Exelixis’s cancer drug cabozantinib as the primary driver for the anticipated earnings beat. This follows what the firm described as ...
SAS has announced the release of JMP ® Genetics, JMP ® Microarray, and JMP ® Proteomics, three specialized genomics products for desktop statistical analysis of DNA, RNA and protein data. The suite of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results